Peripheral arterial disease is the kind of condition that hides in plain sight. It narrows the arteries in the legs, quietly raising the risk of heart attack, stroke and, in the worst cases, amputation - and it often produces no symptoms until it is advanced. Catching it early usually means a specialist, a Doppler machine and time most primary-care visits do not have. Semler Scientific built its business on a simpler idea: what if the test took five minutes and could be run in any exam room?
That idea became QuantaFlo, an FDA-cleared device that clips an optical sensor onto a patient's fingers and toes, measures blood volume as it pulses through the extremities, and plots the result on a chart that estimates the probability of PAD. It works, in effect, like a digital version of the ankle-brachial index, the long-standing cuff-based benchmark - but without cuffs, and in a fraction of the time. Studies have reported high concordance with Doppler-based methods. For a busy clinic, that combination of speed and evidence is the whole pitch.
Founded in 2007 and public on the Nasdaq under the ticker SMLR, Semler spent most of its life as exactly what it looked like: a small, profitable medical-device company. Then, in 2024, it did something that no healthcare company its size had done before. It decided its balance sheet was as much a product as its hardware - and it started buying Bitcoin.
01What the company actually does
Strip away the headlines and Semler Scientific is a point-of-care diagnostics company. Its flagship, QuantaFlo, received FDA 510(k) clearance in 2015 and became a widely used screening tool for peripheral arterial disease. The value proposition is narrow and practical: give a general practitioner, an internist or a home-visit nurse a way to flag vascular trouble on the spot, without referring the patient out and without the equipment overhead of a vascular lab.
Because the disease is common and under-diagnosed, screening at scale is the point. QuantaFlo was designed to slot into routine visits rather than specialist appointments, which is why it found its largest market not in hospitals but in the annual health assessments that insurers run for their members.
The mechanics are unglamorous by design. An optical sensor reads the change in blood volume with each pulse; software converts that waveform into a plethysmography chart and a probability score. There is no gel, no cuff sequence, no trained sonographer. That is deliberate - the harder a screen is to run, the fewer patients get screened, and PAD is exactly the sort of condition where an easy test in a general clinic can surface cases that a referral-only pathway would miss.
02Who buys it
Semler's customers have been concentrated among Medicare Advantage health plans and the vendors that run in-home health evaluations for them. Large insurers deployed QuantaFlo across clinics and home visits as part of nationwide PAD screening programs. That concentration was a strength and a risk at once: a single large customer accounted for roughly half of revenue in 2025 before beginning to reduce its use of the device late that year - a reminder that a business built on a handful of big buyers can shrink as fast as it grew.
When one customer is half your revenue, a policy change on their side is a revenue cliff on yours. Semler told investors to expect a sharp drop after its largest customer pulled back in late 2025.
03How it makes money
The model reads more like software than hardware. Rather than one-off equipment sales, Semler licenses the QuantaFlo platform through a mix of fixed-fee licenses and variable, per-use fees, supplemented by hardware and support. The recurring, usage-based structure is what gave the company steady cash generation - and, eventually, the surplus that funded its second act. Full-year 2024 revenue was $56.3 million, down from $68.2 million in 2023.
Disclosed Bitcoin holdings
04The pivot that changed the story
In May 2024, Semler's board designated Bitcoin as the company's primary treasury reserve asset and made its first purchase - 581 BTC for about $40 million. The move was openly modeled on the playbook that Michael Saylor's MicroStrategy had made famous: treat corporate cash not as something to park in short-term instruments but as something to convert into a scarce asset the company believes will hold value over time.
The architect was chairman Eric Semler, who had bluntly described the pre-pivot business as a profitable but stagnant "zombie company." The reasoning he offered was straightforward.
From there the accumulation moved quickly. By the end of 2024 the company held 3,192 BTC. By mid-2025 it had passed 5,000, and in July 2025 it became the 14th-largest public corporate holder of Bitcoin after a fresh purchase. Along the way it laid out an ambition to reach five figures of BTC and, eventually, tens of thousands - funded through operating cash, equity offerings and debt.
The market noticed. A stock that had traded like a quiet, cash-generative device business began to move with the crypto market, and the company started reporting a "Bitcoin yield" metric alongside its clinical results. It filed a large shelf offering in 2025 to give itself room to keep buying. For a business whose day job was measuring whether blood reaches the toes, it was a striking reorientation of what the company considered its most important number.
04bThe expertise behind it
For a company that made headlines for a finance decision, Semler's roots are clinical. It was founded in 2007 to commercialize non-invasive blood-flow assessment, and its long-time chief executive, Douglas Murphy-Chutorian, is a cardiologist and prolific inventor who has guided a long list of products through regulatory approval. That mix - a physician-founder's instinct for what a clinic will actually use, paired with the discipline of FDA clearance - is what turned a measurement idea into a device that health plans were willing to deploy nationwide.
The Bitcoin strategy layered a second, very different kind of expertise on top: capital allocation. Chairman Eric Semler treated the treasury like a portfolio decision rather than a housekeeping task, and the company hired dedicated staff to run the accumulation program. It is rare to find both skill sets under one roof, and rarer still at a company of roughly 59 people.
05What sets it apart
On the clinical side, QuantaFlo's differentiation is speed and simplicity: a validated PAD screen that fits inside a normal visit and does not require a vascular lab. Plenty of companies make ankle-brachial index systems and Doppler tools; few package the measurement into something a non-specialist can run in minutes and read at a glance.
On the financial side, the differentiation is stranger. Semler is one of the very few healthcare companies to run a serious corporate Bitcoin treasury, which means its stock behaves partly like a medical-device business and partly like a leveraged bet on a single asset. For investors, that is either diversification or double exposure, depending on the day.
In September 2025, Semler finalized a roughly $29.75 million settlement with the U.S. Department of Justice over Medicare claims tied to its tests, resolving the matter with no admission of wrongdoing.
06Two treasuries become one
The final turn came in September 2025, when Strive, Inc. (Nasdaq: ASST) - itself a Bitcoin treasury company - agreed to acquire Semler in an all-stock deal at a large premium. Shareholders approved it in January 2026. The combination created a treasury of roughly 12,798 BTC and was billed as the first-ever merger between two publicly traded Bitcoin treasury companies. A device maker that began by measuring blood flow ended up as half of one of the larger corporate Bitcoin balance sheets in public markets.
Illustrative revenue structure. Semler's core is recurring QuantaFlo licensing rather than one-time equipment sales.
07Where it fits in the market
Semler sits at an unusual crossroads. In diagnostics, it competes on the ground held by ankle-brachial index systems, Doppler ultrasound and other point-of-care cardiovascular screening tools, with a bet that faster, in-office testing expands who gets checked. In capital markets, it sits alongside MicroStrategy and a growing list of corporate Bitcoin holders, judged as much on treasury strategy as on product.
It is genuinely two things at once - a screening company that wants clinicians to catch vascular disease before it turns into an emergency, and a holding company whose fortunes rise and fall with the price of one asset. Whether that dual identity looks like conviction or like risk depends heavily on where Bitcoin trades on any given morning. What is not in dispute is that a 59-person company managed to be both, and to matter in two markets that rarely overlap.